• <progress id="ete9x"></progress>
  • <dd id="ete9x"></dd>

    <dd id="ete9x"><track id="ete9x"></track></dd><tbody id="ete9x"><noscript id="ete9x"></noscript></tbody>

    Ideal Medicine attaches great importance to the research and development of psychotropic drugs. It has obtained the pre-approval from the National Medical Products Administration [National Medical Products Administration-(NMPA)] to establish a psychotropic drug research laboratory.

    The second-class psychotropic drug "phenobarbital tablets" successfully passed the relocation: On August 27, 2018, the Shanghai Food and Drug Administration approved the relocation production application of "phenobarbital tablets" and agreed to the production address of this product Changed from No. 1888, Zhuxin Road, Jinshan Industrial Zone, Shanghai to No. 428, Xihan Road, Fengxian District, Shanghai.

    The second-class psychotropic drug "phenobarbital tablets" successfully obtained the drug GMP certificate: On February 2, 2019, Shanghai Ideal Pharmaceutical Co., Ltd. successfully obtained the "drug GMP certificate".

    Approval for the approval of the first-class psychotropic drug research laboratory project: Shanghai Ideal Pharmaceutical Co., Ltd. obtained the first-class psychoactive drug experimental research approval approved by the State Drug Administration on June 11, 2019, with the approval number: TYL2019-0139.

    The second-class psychotropic drug caffeine tablets project approval was approved: Shanghai Ideal Pharmaceutical Co., Ltd.'s second-class psychoactive drug "caffeine tablets" was approved for experimental research by the National Medical Products Administration on November 6, 2019, approval number: TYL2019- 0240.

    The consistency evaluation of the second-class psychotropic drug "phenobarbital tablets" entered the key link: the formal BE was successfully registered in CDE, registration numbers: CTR20200901, CTR20201416, and the experimental status has been officially launched.